SMYD2在恶性肿瘤中的研究进展

doi:10.11904/j.issn.1002-3070.2022.03.015

Abstract

Abstract: Lysine methyltransferase 2(SMYD2)is a kind of special lysine methyltransferase containing SET(Suppressor of variegation,Enhancer of zeste,Trithorax)domain and MYND(Myeloid-nervy-deaf1)domain.Through post-translational modifications of histones and other proteins,SMYD2 plays a key role in epigenetics,body development,and carcinogenesis.In recent years,the role of SMYD2 in malignant tumors has received increasing attention.A number of studies have shown that SMYD2 plays an important role in the occurrence,development and metastasis of ovarian cancer,breast cancer,colon cancer,renal cell carcinoma and other malignant tumors.This article describes the research progress of SMYD2 in malignant tumors in recent years.

Key words: Lysine methyltransferase 2, Tumor, High expression, Methylation

CLC Number:

R737.3

YANG Nan, WANG Zhao, ZHANG Yu, ZHANG Yunyan. Research progress of SMYD2 in malignant tumors[J]. Journal of Practical Oncology, 2022, 36(3): 273-277.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.03.015

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I3/273

References

1 Zhang B,Liao L,Wu F,et al.Synthesis and structure-activity relationship studies of LLY-507 analogues as SMYD2 inhibitors[J].Bioorg Med Chem Lett,2020,30(22):127598.
2 Leinhart K,Brown M.SET/MYND lysine methyltransferases regulate gene transcription and protein activity[J].Genes(Basel),2011,2(1):210-218.
3 Chandramouli B,Melino G,Chillemi G.SMYD2 conformational changes in response to p53 binding:role of the C-terminal domain[J].Mol Oncol,2019,13(6):1450-1461.
4 Brown MA,Sims RJ,Gottlieb PD,et al.Identification and characterization of SMYD2:a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex[J].Mol Cancer,2006,5:26.
5 Wu J,Cheung T,Grande C,et al.Biochemical characterization of human SET and MYND domain-containing protein 2 methyltransferase[J].Biochemistry,2011,50(29):6488-6497.
6 Spellmon N,Sun X,Sirinupong N,et al.Molecular dynamics simulation reveals correlated inter-Lobe motion in protein lysine methyltransferase SMYD2[J].PLoS One,2015,10(12):e0145758.
7 Bannister AJ,Schneider R,Myers FA,et al.Spatial distribution of di-and tri-methyl lysine 36 of histone H3 at active genes[J].J Biol Chem,2005,280(18):17732-17736.
8 Rao B,Shibata Y,Strahl BD,et al.Dimethylation of histone H3 at lysine 36 demarcates regulatory and nonregulatory chromatin genome-wide[J].Mol Cell Biol,2005,25(21):9447-9459.
9 Abu-Farha M,Lambert JP,Al-Madhoun AS,et al.The tale of two domains:proteomics and genomics analysis of SMYD2,a new histone methyltransferase[J].Mol Cell Proteomics,2008,7(3):560-572.
10 Fan JD,Lei PJ,Zheng JY,et al.The selective activation of p53 target genes regulated by SMYD2 in BIX-01294 induced autophagy-related cell death[J].PLoS One,2015,10(1):e0116782.
11 Saddic LA,West LE,Aslanian A,et al.Methylation of the retinoblastoma tumor suppressor by SMYD2[J].J Biol Chem,2010,285(48):37733-37740.
12 Obermann WMJ.A motif in HSP90 and P23 that links molecular chaperones to efficient estrogen receptor alpha methylation by the lysine methyltransferase SMYD2[J].J Biol Chem,2018,293(42):16479-16487.
13 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249.
14 Engqvist H,Parris TZ,Kovacs A,et al.Validation of novel prognostic biomarkers for early-stage clear-cell,endometrioid and mucinous ovarian carcinomas using immunohistochemistry[J].Front Oncol,2020,10:162.
15 Kojima M,Sone K,Oda K,et al.The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells[J].Oncol Lett,2020,20(5):153.
16 Kukita A,Sone K,Oda K,et al.Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas[J].Biochem Biophys Res Commun,2019,513(2):340-346.
17 Song J,Liu Y,Chen Q,et al.Expression patterns and the prognostic value of the SMYD family members in human breast carcinoma using integrative bioinformatics analysis[J].Oncol Lett,2019,17(4):3851-3861.
18 Liu L,Kimball S,Liu H,et al.Genetic alterations of histone lysine methyltransferases and their significance in breast cancer[J].Oncotarget,2015,6(4):2466-2482.
19 Li LX,Zhou JX,Calvet JP,et al.Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression[J].Cell Death Dis,2018,9(3):326.
20 Lai Y,Yang Y.SMYD2 facilitates cancer cell malignancy and xenograft tumor development through ERBB2-mediated FUT4 expression in colon cancer[J].Mol Cell Biochem,2020,10:1007.
21 Meng F,Liu X,Lin C,et al.SMYD2 suppresses APC2 expression to activate the Wnt/|-catenin pathway and promotes epithelial-mesenc hymal transition in colorectal cancer[J].Am J Cancer Res,2020,10(3):997-1011.
22 Ren H,Wang Z,Chen Y,et al.SMYD2-OE promotes oxaliplatin resistance in colon cancer through MDR1/P-glycoprotein via MEK/ERK/AP1 pathway[J].Onco Targets Ther,2019,12:2585-2594.
23 Pires-Luis AS,Vieira-Coimbra M,Vieira FQ,et al.Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication[J].Epigenetics,2015,10(11):1033-1043.
24 Yan L,Ding B,Liu H,et al.Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma[J].Theranostics,2019,9(26):8377-8391.
25 Brown MA,Edwards MA,Alshiraihi I,et al.The lysine methyltransferase SMYD2 is required for normal lymphocyte development and survival of hematopoietic leukemias[J].Genes Immun,2020,21(2):119-130.
26 Oliveira-Santos W,Rabello DA,Lucena-Araujo AR,et al.Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia[J].Tumour Biol,2016,37(7):9473-9481.
27 Sakamoto LH,Andrade RV,Felipe MS,et al.SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor[J].Leuk Res,2014,38(4):496-502.
28 Zipin-Roitman A,Aqaqe N,Yassin M,et al.SMYD2 lysine methyltransferase regulates leukemia cell growth and regeneration after genotoxic stress[J].Oncotarget,2017,8(10):16712-16727.
29 Sun JJ,Li HL,Ma H,et al.SMYD2 promotes cervical cancer growth by stimulating cell proliferation[J].Cell Biosci,2019,9:75.
30 石琳娜,隋红.原发性肝癌免疫检查点抑制剂治疗的进展与挑战[J].实用肿瘤学杂志,2020,34(6):560-564.
31 Zuo SR,Zuo XC,He Y,et al.Positive expression of SMYD2 is associated with Poor prognosis in patients with primary hepatocellular carcinoma[J].J Cancer,2018,9(2):321-330.

[1]	YU Xiaolan, LIU Yan, LIU Jiaren. Research progress in the inhibitory effects of plant anthocyanins on tumors [J]. Journal of Practical Oncology, 2022, 36(3): 245-249.
[2]	LIU Xinxin, YAO Xinhui, SUN Yuefeng, MIU Meiqi, CHEN Jing. Research progress in the role of chemokine CCL20 in breast cancer microenvironment [J]. Journal of Practical Oncology, 2022, 36(3): 250-254.
[3]	ZHENG Yanli, HE Jianxia. Research progress of DNA methylation in diffuse large B-cell lymphoma [J]. Journal of Practical Oncology, 2022, 36(3): 259-262.
[4]	WANG Leilei, CHEN Hui. Progress in the treatment of T1 high-grade urothelial carcinoma [J]. Journal of Practical Oncology, 2022, 36(3): 283-287.
[5]	ZHANG Ning, LIN Liuya, LI Sifan, ZHU Meng. Effects of miR-106a targeting TIMP2 on proliferation,metastasis and EMT of human gastric cancer [J]. Journal of Practical Oncology, 2022, 36(2): 105-110.
[6]	WU Fangfang, ZHENG Tongsen. Research status and prospect of adjuvant therapy for biliary tract malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 156-161.
[7]	LIU Yu, YU Xingxin, GENG Zhida, CHEN Zhengliang, HUI Peng, LIANG Yingjian. The role of liver fibroblasts in the occurrence and development of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2022, 36(2): 167-172.
[8]	TANG Ju, SHANG Lihua. The relationship between BMI and the efficacy of immune checkpoint inhibitors in the treatment of malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 188-192.
[9]	WANG Yanping, QIU Lin, WU Meng, SA Rina. Analysis of the incidence and mortality of malignant tumors in Shaanxi province in 2016 [J]. Journal of Practical Oncology, 2022, 36(1): 1-6.
[10]	DONG Lina, LIANG Tian, ZHANG Xian, ZHANG Guangmei. Research progress on tropism of ovarian cancer to fat-rich omentum organs [J]. Journal of Practical Oncology, 2022, 36(1): 54-58.
[11]	SHI Jingtong, CHEN Minjie, SUN Yihua. Research progress in the role of malignant tumor-derived exosomes in the M2 polarization of macrophages [J]. Journal of Practical Oncology, 2022, 36(1): 59-63.
[12]	MENG Xin, LU Jinyue, ZHANG Ailin, HE Luwen. Research progress on antitumor medicinal substances and pharmacological activities of Radix Actinidia chinensis [J]. Journal of Practical Oncology, 2022, 36(1): 69-73.
[13]	WANG Yang, LI Guodong, TANG Qingchao, LIU Ming. Research progress of acidosis in colorectal malignant tumors [J]. Journal of Practical Oncology, 2022, 36(1): 74-78.
[14]	MU Guannan, MA Qiang. The role of NK cell polarization in endometrial cancer [J]. Journal of Practical Oncology, 2021, 35(6): 534-537.
[15]	YANG Kaiyan, WEI Yongchang, YANG Qiuyun, TANG Fengzhu. Research progress in immunotherapy of nasopharyngeal carcinoma [J]. Journal of Practical Oncology, 2021, 35(6): 542-546.

Research progress of SMYD2 in malignant tumors

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments